Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.37 |
| ▸ | SCN1A | P35498 | 3/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.36 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531709 | 0.90 | SCD (0.41) | ARCYP3A4 | |
| SCHEMBL5529479 | 0.88 | SCN1A (0.40) | ARSCN1ASCN8AMCHR1HCRTR2 | |
| SCHEMBL8238859 | 0.86 | AR (0.35) | ARSCN1ASCN8ATIPARPMCHR1 | |
| SCHEMBL5528243 | 0.85 | SCN8A (0.48) | SCN1ASCN8A | |
| SCHEMBL5532960 | 0.84 | SCN8A (0.38) | SCN1ASCN8ATIPARPMCHR1 | |
| SCHEMBL5532727 | 0.82 | HRH3 (0.42) | ARCYP3A4 | |
| SCHEMBL5530874 | 0.80 | SCD (0.43) | ARCYP3A4 | |
| SCHEMBL5521962 | 0.79 | SCN8A (0.43) | ARSCN1ASCN8A | |
| SCHEMBL5529940 | 0.77 | AR (0.40) | AR | |
| SCHEMBL5530556 | 0.77 | TTR (0.40) | SCN1ASCN8AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071055-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | AR 4698/4885SCN1A 89/4885SCN8A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.